logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Laurus Labs Ltd

Laurus Labs

Large Cap•6,007 Employees•IPO 2016
Current Price
₹1114.35
-15.15 (-1.34%)Updated
NSE :LAURUSLABS
BSE :540222
Sector :Pharmaceuticals
Today's Range
1110.05
₹1114.35
indicator
1136.8
52 Week Range
52W Low₹572.25
52W High₹1144.85
₹1114.35
indicator
Downside94.73%
Upside2.74%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹54,722.56 Cr
Market Cap
Total market value of company
P/E Ratio
64.89
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
9.46
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹15.61
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
9.24%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
9.15%
ROCE
Return on Capital Employed. >15% is good
Net Margin
12.55%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
6.75%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
14.42%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
35.10%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
883.00%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.62
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹82.94
Book Value
Net asset value per share
Dividend Yield
0.12%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
27.60%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

4 points
  • •Laurus Labs demonstrates robust quarterly sales growth, with a significant 35.10% increase in the latest quarter. This indicates strong market demand and effective sales strategies, suggesting a healthy growth trajectory for the company.
  • •The company reported an exceptional 883.00% increase in quarterly profit, signaling substantial improvements in profitability. This strong performance highlights effective operational management and potential for sustained future growth.

Weaknesses

4 points
  • •The company's high P/E ratio of 75.80 suggests a premium valuation compared to many industry peers, potentially indicating that the stock is overvalued. This could limit future upside if earnings growth slows down.
  • •Laurus Labs exhibits a relatively low Return on Capital Employed (ROCE) of 9.15% and Return on Equity (ROE) of 7.45%, which are significantly below most industry peers. This indicates less efficient capital utilization.

Opportunities

3 points
  • •The pharmaceutical sector, where Laurus Labs operates, is poised for sustained growth driven by increasing global healthcare expenditure, rising demand for generics, and advancements in drug discovery and development.
  • •Consistent increase in FII and DII holdings over recent quarters, with FIIs now at 26.17% and DIIs at 11.72%, signals growing institutional confidence and potential for further capital infusion into the company.

Threats

4 points
  • •Laurus Labs faces intense competition from larger, well-established players like Sun Pharma and Divi's Lab, which boast higher market caps and often superior profitability metrics, potentially limiting market share growth.
  • •The pharmaceutical industry is subject to stringent regulatory changes and approvals, which can impact product development, manufacturing, and market access, posing a significant compliance and operational risk.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹1184.25+₹69.90+6.27%
R3₹1157.50+₹43.15+3.87%
R2₹1147.15+₹32.80+2.94%
R1₹1130.75+₹16.40+1.47%
PIVOT₹1120.406.050.54%
CURRENT₹1114.35--
S1₹1050.50-₹63.85-5.73%
S2₹1077.25-₹37.10-3.33%
S3₹1093.65-₹20.70-1.86%
S4₹1104.00-₹10.35-0.93%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
1.49M
(21 Apr 2026)
-18.2% vs avg
Delivery %
58.6%
(21 Apr 2026)
+11.8% vs avg
Avg Volume (20D)
1.83M
(19 Mar - 21 Apr)
20-day average
Avg Delivery %
46.9%
(19 Mar - 21 Apr)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Lupin Ltd
52.10 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %

Peer Comparison

Company Name
ABBOTINDIA
Abbott India Ltd
AJANTPHARM
Ajanta Pharma Ltd
ALKEM
Alkem Laboratories Ltd
AUROPHARMA
Aurobindo Pharma Ltd
COHANCE
Cohance Lifesciences Ltd
EMCURE
Emcure Pharmaceuticals Ltd
GLAND
Gland Pharma Ltd
GLAXO
Glaxosmithkline Pharmaceuticals Ltd
GLENMARK
Glenmark Pharmaceuticals Ltd
IPCALAB
Ipca Laboratories Ltd
JBCHEPHARM
J B Chemicals & Pharmaceuticals Ltd
LUPIN
Lupin Ltd
MANKIND
Mankind Pharma Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd

About

LAURUSLABS

Laurus Labs Ltd

Laurus Labs Limited is a prominent Indian pharmaceutical company specializing in the manufacturing and sale of active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs) globally. Their core business revolves around providing generic APIs and oral solid dosage forms across a diverse range of therapeutic areas. This includes crucial medications for conditions such as HIV/AIDS (anti-retrovirals), diabetes, cardiovascular diseases, asthma, ophthalmic issues, cancer (oncology), gastrointestinal problems, and Hepatitis C.

The company's API production caters to a wide spectrum of therapeutic needs, demonstrating a strong commitment to addressing various healthcare challenges. Their focus on generics allows them to offer cost-effective alternatives to brand-name medications, increasing accessibility to essential medicines both domestically and internationally. This strategy contributes significantly to Laurus Labs' market position and competitive advantage.

Beyond APIs and finished formulations, Laurus Labs extends its expertise into the realm of biotechnology services. This diversification allows them to leverage their scientific capabilities in areas such as nutraceuticals, dietary supplements, alternative food proteins, and cosmeceuticals. The company's involvement in these fields showcases a forward-looking approach to expanding its product portfolio and tapping into emerging market segments.

Furthermore, Laurus Labs is engaged in the development of innovative enzymatic solutions for industrial biotechnology applications. This highlights their commitment to research and development, driving technological advancements within the broader biotechnology sector. Their work with animal origin-free recombinant proteins and enzymes for biopharmaceuticals signifies a dedication to producing high-quality, safe, and ethically sourced products for the pharmaceutical industry.

Finally, Laurus Labs offers comprehensive business support services specifically targeted at the pharmaceutical industry. The nature of these services isn't explicitly detailed but likely includes functions such as regulatory support, logistics, and potentially contract manufacturing or research collaborations. This completes their business model, rounding out their offerings with crucial support functions that strengthen their overall position within the pharmaceutical ecosystem.

COMPANY FACTS - LAURUSLABS

Registered Address

2nd Floor, Serene Chambers,, Road No. 7, Banjara Hills,

Hyderabad

TELANGANA

IN

Tel: 914039804333

Website:https://www.lauruslabs.com/

Investor Relations:http://www.lauruslabs.com/investors.html
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 6,007

IPO Date: 19/12/2016

MANAGEMENT - LAURUSLABS

Dr. Ravindranath Kancherla

Non-Executive Independent Chairman of the Board

Dr. Satyanarayana Chava

Chief Executive Officer, Executive Director

Mr. Venkata Ravi Vantaram

Chief Financial Officer, Executive Director

Dr. V. Uma Maheswer Rao

President Chemical R and D

Mr. Srinivasa Suryadevara

President - Manufacturing and Operations

Mr. Thomas Versosky

President - FDF, North America

Mr. Jyothi Basu Abbibeni

Executive Vice President - Chemical R and D

Mr. Narasimha Chava

Executive Vice President - Human Resources

Mr. Rajaram Iyer

Executive Vice President Portfolio Management

Mr. Martyn James Peck

Executive Vice President Business Development

Mr. Sita Ramaiah

Executive Vice President - Finance

Mr. Narasimha Rao Dvl

Executive Vice President - Synthesis

Investor Questions Answered

Laurus Labs Ltd (LAURUSLABS) Stock FAQs

Get answers to the most common questions about Laurus Labs Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Laurus Labs Ltd (LAURUSLABS) is ₹1,114.35. Today, the stock has declined by ₹15.15 (1.34%), trading in a range of ₹1,110.05 to ₹1,136.8. The stock opened at ₹1,127.65 with a trading volume of 14,93,267 shares.
Laurus Labs Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹54,722.56 crores, P/E ratio of 64.89, ROE of 9.24%, and ROCE of 9.15%. The dividend yield stands at 0.12%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Laurus Labs Ltd (LAURUSLABS) is ₹1,144.85, while the 52-week low is ₹572.25. Currently trading at ₹1,114.35, the stock is 94.7% away from its 52-week low and 2.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Laurus Labs Ltd stock at ₹1,114.35 depends on multiple factors. The stock is currently trading with a P/E ratio of 64.89 and P/B ratio of N/A. Today's performance shows a loss of 1.34%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Laurus Labs Ltd offers a dividend yield of 0.12%, which means for every ₹100 invested at the current price of ₹1,114.35, you can expect to receive approximately ₹0.12 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Laurus Labs Ltd's key financial metrics include: P/E Ratio: 64.89, P/B Ratio: N/A, ROE: 9.24%, ROCE: 9.15%, Dividend Yield: 0.12%, EPS: ₹15.61, Book Value: ₹82.94, Debt-to-Equity: 0.62, and Current Ratio: N/A. The company's market cap stands at ₹54,722.56 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Laurus Labs Ltd stock opened at ₹1,127.65 and is currently trading at ₹1,114.35, showing a decline of ₹15.15 (1.34%). The intraday high is ₹1,136.8 and low is ₹1,110.05. The trading volume stands at 14,93,267 shares, indicating strong market participation today.
Laurus Labs Ltd has a Price-to-Earnings (P/E) ratio of 64.89, which means investors are willing to pay ₹64.89 for every ₹1 of earnings. With an EPS of ₹15.61, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Laurus Labs Ltd has a market capitalization of ₹54,722.56 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹1,114.35) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Laurus Labs Ltd has a book value of ₹82.94 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,114.35, which is 1243.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Laurus Labs Ltd has a Return on Equity (ROE) of 9.24% and Return on Capital Employed (ROCE) of 9.15%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Laurus Labs Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Laurus Labs Ltd has a debt-to-equity ratio of 0.62, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Laurus Labs Ltd has an Earnings Per Share (EPS) of ₹15.61, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,114.35 and P/E ratio of 64.89, investors are paying 64.89 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Laurus Labs Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Laurus Labs Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Laurus Labs Ltd stock, consider: 1) Fundamental Analysis - Review P/E (64.89), ROE (9.24%), debt-to-equity (0.62), and growth rates. 2) Technical Analysis - Check 52-week range (₹572.25 - ₹1144.85), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1114.35) with book value (₹82.94) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Laurus Labs Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,114.35 is 55617x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Laurus Labs Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹572.25 - ₹1144.85). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.62 indicates leverage. 4) Liquidity Risk - Based on trading volume of 14,93,267 shares. 5) Valuation Risk - P/E of 64.89 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Laurus Labs Ltd operates in the industry with key metrics: P/E ratio of 64.89, ROE of 9.24%, market cap of ₹54,722.56 crores, and dividend yield of 0.12%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.62), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Laurus Labs Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,114.35, with a 52-week range of ₹572.25 to ₹1144.85. Based on fundamentals like P/E (64.89), ROE (9.24%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Laurus Labs Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1114.35. 2) Fundamental Deterioration - Declining ROE (currently 9.24%), increasing debt (D/E: 0.62), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Laurus Labs Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.12%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.